Epigenomic regulation of oncogenesis by chromatin remodeling

Area of Science:

• Molecular Biology
• Epigenetics
• Cancer Research

Background:

• Gene expression dysregulation is a key driver of cancer initiation, progression, and therapeutic resistance.
• Cancer phenotypes arise from altered cellular functions of genes, histones, and chromatin remodeling complexes.
• Chromatin remodelers integrate cellular signals to control gene activity, and their dysregulation contributes to oncogenesis.

Purpose of the Study:

• To review recent advancements in understanding the role of chromatin remodeling components in human tumor growth and progression.
• To highlight the dysregulation of chromatin remodelers as a central mechanism in oncogenesis.
• To explore the potential of targeting chromatin remodelers and bromodomains as novel anti-cancer therapeutic strategies.

Main Methods:

• Literature review of genetic and biochemical evidence.
• Analysis of the role of chromatin remodelers in signal integration and gene activity control.
• Examination of the implications of epigenetic code interpretation by chromatin remodelers, modifying enzymes, and protein-protein interactions.

Main Results:

• Widespread dysregulation of chromatin remodelers leads to inappropriate gene expression and oncogenesis.
• Chromatin remodelers are critical in integrating extracellular and cytoplasmic signals to modulate gene expression.
• Selective targeting of chromatin remodelers and bromodomains presents a promising avenue for future cancer therapies.

Conclusions:

• Dysregulation of chromatin remodeling components is a fundamental mechanism driving human cancer.
• Targeting epigenetic regulators like chromatin remodelers and bromodomains offers novel therapeutic opportunities.
• These epigenetic targets can be exploited in single-agent or combination therapies to combat cancer and overcome resistance.